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ABSTRACT 
Platelets are essential for haemostasis and thrombosis, but also play a major role in 
angiogenesis. Activated platelets recruit progenitor cells and induce differentiation into 
endothelial progenitor cells (EPCs), which contribute importantly to vascular regeneration 
and endothelium reparation. However, the interactions between platelets and EPCs are poorly 
understood. Therefore, aims of the present thesis work are to investigate platelet angiogenic 
activities, and to study the influence and mechanisms of platelet-regulated EPC angiogenic 
properties. 
We have elucidated that platelets promoted EPC angiogenesis via the glycoproteins on the 
platelet surface, and identified that platelet tetraspanin CD151 and integrin α61, as well as 
EPC α61 were required for platelet-enhanced EPC angiogenesis. Moreover, it has been 
shown that platelets exerted the enhancement via Src-PI3K signalling pathway of EPCs. 
Platelets contain both pro- and anti-angiogenic factors, which are stored in separate α-
granules and distinctly release upon different stimulation. In paper II, we characterized that 
pro-angiogenic and anti-angiogenic regulators were mostly stored in separate α-granules. 
Furthermore, we found that protease-activated receptor (PAR) 1, adenosine diphosphate 
(ADP), and GPVI stimulation induced platelet secretion of pro-angiogenic regulators, 
whereas PAR4 stimulation selectively induced platelet secretion of anti-angiogenic regulators. 
In paper III, we determined if PAR1-stimulated platelet releasate (PAR1-PR) and PAR4-PR 
differently regulate angiogenic properties of EPCs. To our surprise, both PAR1-PR and 
PAR4-PR enhanced EPC migration and tube formation. PAR1-PR enhanced vasculogenesis 
more potently than PAR4-PR, and the enhancements required a cooperation of multiple 
platelet-derived angiogenic regulators. 
Platelets retain mRNAs from the megakaryocytes, and use these mRNAs as templates for de 
novo protein synthesis upon stimulation. In paper IV, we observed that thrombin stimulation 
induced SDF-1α mRNA maturation, which led to de novo synthesis of SDF-1α after 
activation. The data suggest that platelets may enhance angiogenesis by de novo synthesis of 
angiogenic regulators after activation. 
Together, the thesis work demonstrates that platelets enhance EPC angiogenic properties via 
both secreted angiogenic regulactors and surface receptors, and that platelets may regulate 
angiogenesis via de novo synthesis of angiogenic regulators after activation. 
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1 INTRODUCTION 
Angiogenesis, the sprouting of new capillaries from pre-existing blood vessels, is closely involved 
in many physiologic and pathologic processes [1]. The formation and persistence of new blood 
vessels is regulated by a complex control system. The basic steps in vessel formation include 
endothelial activation, proliferation, and migration, which are followed by the development of a 
vascular cord, lumen formation, stabilization, and finally vessel maturation [2, 3]. Identification of 
endothelial progenitor cells (EPCs) in the peripheral blood has highlighted an alternative 
mechanism of vessel formation based on the recruitment of bone marrow-derived EPCs [4-6]. 
Accumulating evidence in the past decade indicates that EPCs play important roles in vascular 
regeneration and endothelium reparation [6-8]. 
Platelets are essential for haemostasis [9]. At the sites of blood vessel injury, platelets are 
activated to induce blood coagulation and form aggregates to prevent haemorrhage and thereby 
protects us from fatal bleeding [10]. Besides their well-known function in haemostasis, platelets 
have been shown to contribute to nonhaemostatic processes, such as wound healing, immunity, 
angiogenesis, atherogenesis, and tumor metastasis [11-13]. More and more evidence shows that 
platelets play an important role in angiogenesis, and EPCs have given an alternative role in 
angiogenesis. Hence, the present thesis is focused on platelet-dependent angiogenic activities and 
how platelets regulate the EPC functions in both in vitro and in vivo experimental settings. 
1.1 PLATELET PHYSIOLOGY 
Platelets are the smallest blood cells, and are discoid anucleated cells (approximately 2-5 µm in 
diameter) shed from megakaryocytes in the bone marrow. Platelets circulate in large numbers 
(200–300109/L) under physiological conditions, and normally remain in the circulation for 
approximately 7 to 10 days. Platelets are in a quiescent state in circulation, and become activated 
by exposure to extracellular matrix (ECM). They adhere to the damaged vessel wall, build up 
platelet aggregates, and form platelet thrombus. These processes restore integrity of the vessel 
wall and stop bleeding, but may also lead to occlusive thrombus formation under 
pathophysiological conditions [14]. 
Although platelets lack nuclei, they are highly organized cells containing all other organelles, such 
as granules, mitochondria, and the cytoskeletal components microtubules and actin filaments. 
Platelets contain three different types of granules; dense granules (δ granules), lysosomes, -
granules [15]. The -granule is the most abundant, comprising 10% of platelet volume with 
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approximately 50–80 -granules per platelet [16]. The -granules contain high molecular weight 
proteins and peptides, such as von Willebrand factor (vWF), fibrinogen, platelet factor 4 (PF4), 
vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), basic 
fibroblast growth factor (bFGF), matrix metalloproteinases (MMPs), thrombospondin 1 (TSP-1) 
and plasminogen activator inhibitor 1 (PAI-1) [13, 17]. The dense granules are smaller and fewer 
than the -granules, and have high morphological variability [18]. Dense granules contain small 
molecules, such as calcium and adenine nucleotides, including adenosine diphosphate (ADP) and 
adenosine triphosphate (ATP). Human platelets also contain a few lysosomes. The organelles 
show acid phosphatase reaction product, and are spherical in form and slightly smaller than α 
granules. Platelets have two specialized tubular systems. The open canalicular system (OCS) is a 
reservoir of platelet membrane, and provides a transportation highway for the release of platelet 
granule contents. The dense tubular system is a calcium storage pool, and is the site for 
thromboxane A2 (TXA2) and prostaglandin syntheses [19].  
Platelet receptors expressed on the cell surface determine the reactivity of platelets with a wide 
range of agonists and adhesive proteins. The integrins are a major class of adhesion and signalling 
molecules that are present on most cell types as well as on platelets. Platelets have six different 
integrins: α2β1, α5β1, α6β1, αLβ2, αIIbβ3, and ανβ3. Among them, αIIbβ3 is the most abundant 
and platelet-specific, which is the principle receptor for fibrinogen [20, 21].  
Another platelet-specific receptor is glycoprotein (GP) Ib/IX/V complex, which is the primary 
receptor for vWF. GP Ib/IX/V complex can also bind to a number of other ligands, such as 
thrombin, P-selectin, factor XI (FXI), FXII, high molecular weight kininogen, as well as some 
bacteria membrane component [22].  
The seven-transmembrane receptor family is the major agonist receptor family on platelets. For 
example, protease-activated receptor-1 (PAR1) and PAR4 are the receptors for thrombin, P2Y12 
and P2Y1 are the receptors for ADP, and thromboxane receptor (TP) α/β is the receptor for TXA2 
[23, 24].  
Immunoglobulin superfamily receptors on human platelets include GPVI and FcγRIIa. GPVI, in 
addition to α2β1, cooperates with FcγRIIa and serves as the signalling receptor for collagen on 
platelets [25]. FcγRIIa has also a role in immunological defense against bacteria, viruses, and 
parasites. The significance of FcγRIIa also lies in the problems caused by a variety of autoimmune 
and alloimmune disorders involving antigen-antibody clusters that cause platelet activation by 
clustering FcγRIIa [26]. 
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 The main C-type lectin receptors on platelets include P-selectin (CD62P) and C-type lectin-like 
receptor-2 (CLEC-2). The main function of P-selectin involves multiple, transient weak 
interactions with carbohydrate ligands expressed on the cells, thereby allowing the development 
of stronger, more stable binding via other ligands and receptors [27]. CLEC-2 has an important 
physiological role in vascular/lymphatic system differentiation [28].  
Tetraspanins are a group of membrane proteins that, as the name implies, contain four membrane-
spanning domains. They are thought to have important functions in signal transduction across the 
cell membrane in complexes with other membrane receptors by playing a critical role in selection 
of components of lipid rafts. Platelets content several members of this group of molecules, but the 
roles of them are still poorly understood. Platelets express at least 4 tetranspanins on the surface, 
CD9 (Tspan 29), CD63 (Tspan 30), CD151 (Tspan 24, platelet and endothelial cell tetraspan 
antigen 3 [PETA-3]) and Tspan32 [29, 30].  
Besides these receptors, platelets express other type receptors on the surface, such as 
thrombopoietin receptor (c-mpl, CD110), PDGF receptor, CD36 (GPIV, GPIIIb), CD40 Ligand 
(CD40L, CD154), and so on. 
1.1.1 Platelet activation 
Platelets are sensitive cells, and can be activated by a number of stimuli. Table 1 lists a panel of 
common agonists and their corresponding receptors on platelets. The potencies of platelet 
agonists differ considerably. Thrombin, the most potent physiological agonist of platelets, 
activates human platelets via the cleavage of PAR1 and PAR4 to induce full platelet activation, 
including platelet shape change, adhesion and aggregation, secretion, as well as vesiculation 
(microparticle generation). Some platelet agonists, such as ATP and epinephrine, are so-called 
weak agonists, which only induce platelet shape change and/or reversible platelet aggregation.  
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Table 1. Main agonists and their receptors of human platelets 
Agonists Receptors Main functions 
thrombin PAR1, PAR4 Induces full platelet activation [31, 32] 
TXA2 TP α/β Acts as a positive feedback lipid mediator 
following platelet activation [33, 34] 
ADP P2Y1, P2Y12 Acts as a positive feedback mediator following 
platelet activation [35-37]; induce reversible 
platelet aggregation [38] 
serotonin (5-HT) 5HT2A Acts as a priming agonist and a positive 
feedback mediator following platelet activation 
[39, 40]  
fibrinogen/fibrin IIb3 Initiates platelet adhesion at low shear [41-43]; 
act as a bridge in platelet-platelet aggregation 
[44, 45] 
vWF GPIb-IX-V Decrease platelet velocity and initial tethering 
at high shear rate [41, 42, 46-48]; act as a 
bridge in platelet-platelet aggregation [49] 
collagen GPVI, 21 For platelet firm adhesion and platelet 
activation at the sites of damaged vessel [41-
43] 
ATP P2X1 Amplifies platelet activation induced by 
collagen, thrombin, and TXA2 [50-53]  
podoplanin CLEC-2 Induces platelet activation, and help the 
separation of the vascular/lymphatic system 
[54]  
Upon a blood vessel injury, ECM proteins, such as vWF and collagen, are exposed to platelets 
and interact with their primary platelet receptors, GPIb-IX-V and GPVI, respectively, to regulate 
initial platelet activation and adhesion [47, 55]. VWF is a large, multimeric GP synthesized by 
endothelial cells (ECs) and megakaryocytes. It is abundant in plasma but does not interact with 
circulating platelets, because the GPIbα binding site on vWF A1 is cryptic. After immobilization 
onto subendothelial surfaces through the binding to ECM components, vWF changes to an active 
conformation upon exposure to hemodynamic forces, and facilitates interaction with GPIbα [56]. 
VWF binding on platelets is reversible, but yet crucial to the sequential steps of platelet adhesion 
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and activation in decreasing platelet velocity, facilitating rolling, and stabilizing platelet adhesion 
through interaction with collagen [45].  
Platelets tether on collagen via GPVI. The ligation further increases affinity and clustering of 
GPVI, and induces inside-out signalling leading to the activation of α2β1, another collagen 
receptor of platelets, and αIIbβ3. These complex adhesion molecule cross-talks coordinate their 
adhesion affinity, and enhance stability of platelet adhesion [57, 58].  
αIIbβ3 (GPIIb/IIIa) is the most abundant membrane protein on platelets, and mediates aggregation 
and firm adhesion of platelets. αIIbβ3 can bind to many ligands, including fibrinogen, 
fibronection, vWF, TSP-1, and CD40L [59]. αIIbβ3 binds to its primary ligand fibrinogen that 
bridges adjacent platelets, leading to platelet aggregation and eventually thrombus formation. 
Moreover, αIIbβ3-ligand binding induces outside-in signalling, which leads to and/or enhances 
further platelet activation, such as cytoskeletal change, platelet spreading, and granule secretion 
[60, 61].  
Except adhesion and aggregation, activated platelets undergo granule secretion. Platelet 
secretion releases granule contents through granule fusion with cell membrane or via OCSs. 
Platelets release a wide range of substances. Table 2 lists a panel of angiogenic regulating 
factors released from platelet  granules. Platelet dense granules release low molecular weight 
substences, such as ADP, ATP and serotonin, which can, in turn, stimulate platelets to amplify 
their activation. Platelet released substances exert various actions on platelet themselves and/or on 
adjacent/distant platelets and other types of cells, to amplify platelet activation and to regulate 
the functions of other cells. The interesting thing is that, platelets may store pro- and anti-
angiogenic regulators in separate -granules, and release differentially upon different stimuli 
according to recent studies [62, 63]. However, there is also evidence showing that platelet 
angiogenic regulators may be randomly packed into platelet α-granules but released with a 
distinct protein cluster [64], and that the distinct release may depend on activation intensity and 
secretion kinetics of platelets [65]. Moreover, distinct platelet angiogenic regulator releases 
upon different stimuli have been reported to exert counteracting effects on angiogenesis [66]. It 
is necessary to investigate if the distinct packaging and releasing of platelet pro- and anti-
angiogenic factors is a general phenomenon. 
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Table 2. Angiogenic regulators that are released from platelets 
 Regulators Main functions 
pro-
angiogenic 
regulators 
VEGF  Promotes EC proliferation, tube formation in vitro, and 
angiogenesis in vivo [66-70] 
PDGF Promotes EC migration and angiogenesis in rat aortic ring 
[69-71] 
bFGF Promotes EC proliferation, tube formation, and 
angiogenesis in rat aortic ring [68-70] 
IGF-1 Promotes angiogenesis in rat aortic ring [67, 72] 
SDF-1 Promotes differentiation of cultured CD34
+
 cells to EPCs 
and induces recruitment of CD34
+
 progenitor cells in vivo 
[73-77] 
MMPs Promote EC tube formation [78, 79] 
S1P Promotes EC proliferation, tube formation, and 
angiogenesis in vivo [79-82] 
ECGF Promotes EC migration and angiogenesis in vivo [83-88] 
anti-
angiogenic 
regulators 
TSP-1 Inhibits EC proliferation and migration, as well as 
stimulates EC apoptosis [89, 90] 
PF4 Inhibits EC proliferation, migration, and angiogenesis in 
vivo [91-94] 
Angiostatin Inhibits EC tube formation and induces EC apoptosis [95, 
96] 
Endostatin Inhibits EC proliferation, migration and tube formation, as 
well as induces EC apoptosis [97-99] 
TIMPs Inhibit EC proliferation and tube formation [100-102] 
 
Platelet activation also triggers the metabolisms of platelet membrane phospholipids, leading to 
the synthesis and release of TXA2 and platelet-activating factor (PAF). Platelet activation is also 
an indispensable component of coagulation cascade. Most remarkedly, membrane 
phosphatidylserine (PS) exposure of activated platelets provides a docking site for FXa and FVa 
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to form prothrombinase complex, which converts prothrombin to thrombin. Thrombin augments 
platelet aggregation via PAR1 and PAR4 on human platelets [103]. 
Platelets lack nuclear DNA, however, they retain some mRNAs from the megakaryocytes, and 
they can use residual mRNAs as templates for de novo protein synthesis, such as Bcl-3, TSP-1, 
and PAI-1, upon activation [104]. Important insights have emerged recently on the regulatory 
controls of gene expression in human platelets, as the maturation of interleukin-1β (IL-1 β) and 
tissue factor (TF) mRNAs has been reported to occur through mRNA splicing after activation 
[105-108].  
Furthermore, besides classical platelet functions in thrombosis and haemostasis, an accumulating 
body of evidence indicates that platelets are not a simple thrombocyte, but are versatile cells 
closely involving in other physiological and pathophysiological processes, such as tissue 
regeneration and angiogenesis. Indeed, platelets have been recognized as a major reservoir of 
angiogenic regulators [13, 17].  
1.2 ENDOTHELIAL CELL AND ENDOTHELIAL PROGENITOR CELL 
ECs are the fundamental elements of the vascular system. They form a single cellular layer that 
lines the interior surface of blood vessels and lymphatic vessels, and serves as a dynamic border 
between circulating blood and the surrounding tissues, and maintains vascular homeostasis 
[109]. On mechanical disruption of this monolayer, the ECM is exposed and gets into contact 
with the blood, which induces platelet adhesion and thrombus formation. The latter facilitates 
leukocyte recruitment and inflammatory responses at the injured sites, and prompt 
atherosclerosis [110]. Indeed, EC dysfunction is an initial step in the atherosclerotic process and 
implicate in the cardiovascular diseases, including hypertension, coronary artery disease (CAD), 
chronic heart failure, peripheral artery disease, diabetes, and thrombosis [111, 112]. Thus, 
integrity maintenance and regeneration of the vascular endothelium is of especial importance. 
EPCs, which are circulating in peripheral blood, share many similar properties with ECs. 
Importantly, they may provide a circulating pool of cells that can form a cellular patch at the site 
of dead/injured ECs. They have a potential to proliferate and to differentiate into mature ECs, 
and improve vascular regeneration and endothelial reparation [6, 113]. EPCs have also been 
studied as biomarkers for cardiovascular disease, and proposed as a potent cell-based therapy 
based on their capacity to stimulate vascular repair under physiological and pathological 
conditions. Increased recruitment and differentiation of EPCs to the sites of vessel injury can 
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promote vascular regeneration and endothelial integrity [7, 8, 113]. In contrast, a reduction in 
circulating EPC number is a surrogate marker for vascular dysfunction, cumulative 
cardiovascular risks, and poor cardiovascular outcomes in patients with CAD [114-117].  
1.2.1 Different types of EPCs and their markers 
EPCs were first isolated using magnetic micro beads by Asahara [4]. Since then, distinctly 
different cell populations have been isolated and called EPCs. These cell populations have 
subsequently been shown to improve vascular function through two mechanisms (i) actual 
incorporation into injured endothelium with formation of a blood vessel and/or (ii) local 
secretion of pro-angiogenic factors with a paracrine effect on the cells actually forming the 
vessel. However, no specific marker can prospectively identify an EPC at present, and thus, the 
origin of the cell cannot be clearly defined. Three different populations of putative human EPCs, 
with a variety of names in the literature, have been defined using for cell culture and cell sorting 
protocols. A summary of different cell populations is given in Table 3. 
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Table 3 Subtypes of Endothelial Progenitor Cells and Their phenotypes 
Circulating angiogenic cells 
(CACs) [7, 118, 119] 
Early outgrowth endothelial 
progenitor cells (CFU-ECs, 
early EPCs and CFU-Hill) 
[4, 6, 115, 120, 121] 
Late outgrowth endothelial 
progenitor cells (BOECs, 
ECFCs, EPDCs, late EPCs, 
and OECs) [5, 6, 113, 120, 
122, 123] 
No colony formation in 
culture 
Colonies appear in 4-9 days 
in culture 
Colonies appear around 7 
day (umbilical blood) and 14 
day (peripheral blood) 
Low proliferative potential Low proliferative potential High proliferative potential 
Do not form vascular tubes in 
vitro on Matrigel 
Do not form vascular tubes 
but incorporate in EC-
formed capillaries in vitro on 
Matrigel 
Form vascular tubes in vitro 
on Matrigel 
Do not form vessels in vivo  Do not form vessels in vivo Form vessels in vivo 
Home to ischemic sites in 
vivo 
Home to ischemic sites in 
vivo 
Home to ischemic sites in 
vivo 
Augment angiogenesis by 
paracrine 
Augment angiogenesis by 
paracrine 
Low cytokine release 
CD34
+/-
, CD133
+
, VEGFR2
+
, 
CD45
+
, CD14
+
, CD115
+
, 
CD31+, ALDH
bright
, acLDL 
uptake, UEA-1 lectin binding 
CD34
+/-
, CD133
+
, 
VEGFR2
+
, CD45
+/-
, CD14
+/-
, CD115
+
, CD31
+
, 
ALDH
bright
, acLDL uptake, 
UEA-1 lectin binding 
CD34
+
, CD133
-
, VEGFR2
+
, 
CD45
-
, CD14
-
, CD115
-
, 
CD31+, ALDH
bright
, acLDL 
uptake, UEA-1 lectin 
binding, CD105
+
, CD146
+
, 
CD144
+
  
 
1.2.2 EPCs for cardiovascular regeneration  
Myocardial infarction (MI) is one of the most frequent causes of morbidity and mortality 
worldwide. Modern medicine has improved prevention of MI and the prognosis following a MI, 
but the mortality rates remain high [124]. Neovascularization is an important adaptation to rescue 
the damaged tissue from severe ischemia. Accumulated evidence has elucidated that EPCs 
provide a postnatal vasculogenetic mechanism for neovascularization and vascular remodelling [6, 
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7]. EPCs have a diverse of physiological functions and participate in the recovery processes of 
myocardial ischemia and infarction [8, 125, 126], limb ischemia [7, 120], wound healing [127, 
128], atherosclerosis [129], and endogenous endothelial repair [130]. Since then, the investigators 
have begun to evaluate the potential therapeutic impacts of EPCs in ischemic diseases.  
1.2.2.1 EPC Transplantation for Peripheral Ischemia 
The transplantation of EPCs significantly improved blood flow recovery and capillary density in 
several animal models of hind limb ischemia. It has been shown that intravenous infusion of ex 
vivo expanded human EPCs (hEPCs) after ischemia improves neovascularization in animal 
models, and that histological examinations confirmed hEPC incorporation and differentiation into 
ECs [7, 131-134]. In contrast, infusion of mature ECs did not affect neovascularization after hind 
limb ischemia [7, 132]. Furthermore, EPC transplantation induces blood flow recovery in the 
ischemic hind limbs of both diabetic mice and rats, suggesting that EPC-mediated 
neovascularization can still occur under disease conditions and thus be applied as a therapeutic 
treatment in the patients who would benefit most [128].  
1.2.2.2 EPC Transplantation for Ischemic Myocardium 
Just as EPC transplantation restored blood flow to ischemic hind limbs, it also induced 
neovascularization after MI. Transplantation of the ex vivo expanded hEPCs to MI model had a 
favourable impact on the preservation of left ventricular function and reduced infraction size [8, 
126]. Similar findings were documented by Kocher et al. [135] by the transplantation of G-CSF–
mobilized CD34
+
 human cells, which contain both haematopoietic stem cells (HSCs) and EPCs. 
The transplantation was shown to improve myocardial function, protect cardiomyocytes against 
apoptosis, and induce myocardial remodelling [135]. In addition, it has been demonstrated that 
EPC therapy improves regional systolic function accompanied by cardiac hypertrophy in porcine 
acute myocardial infarction (AMI) models [136]. 
1.2.2.3 EPC Transplantation in Humans 
Initial results from clinical trials assessing the safety and feasibility of autologous progenitor cell 
transplantation are rather promising. A pilot clinical trial showed that transplantation of adult 
progenitor cells by intracoronary infusion was feasible and safe in patients with AMI, and may 
have beneficial effects for postinfarction remodelling processes. Since then, more and more 
clinical trials have been showing that intracoronary infusion of progenitor cells (either BMCs/ 
BMMNCs [bone marrow-derived mononuclear cells] or CPCs [circulating progenitor cells]) are 
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safe and feasible in patients after AMI, and have disclosed a potency-effect relationship between 
cell therapy and long-term outcome in patients with AMI [137-145]. 
Although the preclinical and clinical studies generally give a strong support to the therapeutic 
potential of EPCs in the treatment of cardiovascular diseases, the clinical application of EPCs is 
limited by several factors. At first, the relative shortage of circulating EPCs makes it difficult to 
expand sufficient number of cells for therapeutic application without inducing the risk of culture-
induced cellular senescence and functional impairment, such as by freezing and thawing [113, 
146]. Furthermore, the availability of EPCs is sensitive to some pathologic state, such as aging 
and diabetes, which are commonly accompanied by cardiovascular diseases [147-150]. This 
severely restricts the ability of autologous EPCs to treat patients with cardiovascular diseases. 
Finally, for a successful therapeutic EPC-based approach, it is essential to get optimal 
quality/quantity of EPCs through various means, such as ameliorating EPC purification and 
expansion methods, improving the administration and cellular application techniques, and 
recovering the disease-based dysfunction and/or senescence of patient-derived EPCs. 
1.2.3 Angiogenesis 
The importance of the circulatory system is evidenced by its early emergence in development. 
In vertebrates, the circulatory system is the first functional organ system to arise and is critical 
in providing adequate oxygen and nutrient delivery to rapidly developing tissues, above what 
can be provided by diffusion alone. The vasculature is formed through three main cellular 
processes: vasculogenesis, angiogenesis and arteriogenesis. Vasculogenesis, the de novo 
formation of blood vessels, gives rise to the first blood vessels, establishing a primary vascular 
plexus. Angiogenesis, the growth of blood vessels from pre-existing blood vessels, allows for 
dramatic expansion of the vascular plexus, while arteriogenesis involves an increase in arterial 
vessel diameter in response to increased blood flow or shear stress. Through these three 
mechanisms a circulatory system is formed and remodelled into a complex vessel system that 
mediates a wide range of vital physiological processes including tissue oxygenation, nutrient 
delivery, waste removal, immune response, temperature regulation, and the maintenance of 
blood pressure. 
Angiogenesis is defined as the formation of new vessels by the sprouting of ECs of pre-existing 
vessels or intussusceptive angiogenesis, the translumenal insertion of tissue pillars within 
existing capillaries to form new vessels. In healthy adults, blood vessels are usually quiescent 
until activated during processes such as wound healing, the female reproductive cycle and 
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pregnancy. Similar to healthy tissues, the growth and progression of cancer is highly dependent 
on angiogenesis. Therefore, anti-angiogenesis can be an effective therapy against tumor growth 
if deprivation of tumor cells from oxygen and nutrients is effectively achieved. It has stirred 
immense interest in the research community, and many therapeutic drugs have been developed 
to target angiogenesis dependent diseases including cancer, ophthalmic diseases, arthritis, 
psoriasis, obesity and obesity-related metabolic diseases.  
Much research into the mechanisms of angiogenesis followed after Judah Folkman proposed the 
inhibition of angiogenesis as a means of tumor treatment [151]. Based on an array of studies, we 
now understand that sprouting angiogenesis is a coordinated series of events centered on ECs 
[152, 153]. Vascular sprouts are led by specialized endothelial “tip cells” that are responsive to 
angiogenic stimuli [154] and connected to endothelial stalk cells that function in tube formation. 
The progression of angiogenesis is initiated by local destruction of the basement membrane of a 
vessel and the dissociation of pericytes from the capillary, followed by migration of tip cells 
toward an angiogenic stimulus. Proliferation and alignment of ECs follows as an EC tube 
formation, establishing a lumen. Pericyte and/or smooth muscle cell association and basement 
membrane deposition mediate vessel stabilization. 
1.2.4 Regulation of angiogenesis 
Angiogenesis is highly governed by the balance of angiogenic stimulators and inhibitors. 
Therefore, pathological conditions, including cancer, diabetes and macular degeneration, arise 
when this balance is tipped. 
1.2.4.1 Pro-angiogenic factors 
1.2.4.1.1 Vascular endothelial growth factor (VEGF) 
VEGFs and theirs receptors are the best-characterized signalling pathway involved in 
regulations of both vasculogenesis and angiogenesis. The VEGF protein family consists of 
VEGF-A (also known as VEGF), VEGF-B, VEGF-C, VEGF-D, and placental growth factor 
(PlGF) [155]. Of these, VEGF-A, originally identified as vascular permeability factor [156] has 
been the most widely studied VEGF family member and has been implicated in both 
vasculogenesis and angiogenesis. Loss of a single VEGF-A allele results in embryonic lethality. 
VEGF-B has been shown to play a central role in cardiac development [157, 158]. VEGF-C and 
VEGF-D promote lymphatic vessel development [159-161] and may also contribute to 
angiogenesis [162, 163]. PlGF, originally identified in the placenta, occurs at low levels in the 
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embryo and adult and has been primarily studied in pathological conditions where it is thought 
to stimulate angiogenesis in coordination with VEGF-A [164]. VEGF-A is present in platelets at 
a concentration of about 0.74±0.37 pg/10
6
 platelets. The major isoforms present in platelets are 
VEGF-A and VEGF-C. Both promote permeability of the vessel wall and serve as a 
chemoattractant for EC sprouting in the initial stage of angiogenic response [225, 226]. 
VEGFs act through three structurally related VEGF receptor tyrosine kinases, denoted VEGFR1 
(Flt1), VEGFR2 (Flk1/KDR), and VEGFR3 (Flt4). The receptors show an overlapping but 
distinct expression pattern. The continuously increased sensitivity of reagents and detection 
methods show that there is a wider expression range of the VEGF receptors than initially 
anticipated. However, there is still an overall pattern of VEGFR1 expression in monocytes and 
macrophages, VEGFR2 in vascular ECs, and VEGFR3 is present in all endothelia during 
development, and in the adult it becomes restricted to the lymphatic endothelium [155, 161, 
165].  
VEGFR1 is widely expressed, and its kinase activity is poor and not required for EC function. 
An important role for VEGFR1 is in negative regulation of VEGFR2 biology, by binding VEGF, 
and in regulation of monocyte migration during inflammation. Moreover, the different VEGFR1 
ligands have quite distinct functions, such as transport of fatty acids and regulation of 
pathological angiogenesis. VEGFR2 is the main VEGF receptor on ECs. VEGFR2 is essential 
for EC biology during development and in the adult, in physiology and pathology. More is 
known about VEGFR2 signalling than for the other VEGFRs. Several small-molecular-weight 
inhibitors of VEGFR2 kinase activity are employed clinically to block pathological 
angiogenesis in cancer [166]. VEGFR3 is critical regulator of lymphendothelial function. Loss-
of-function VEGFR3 mutants in humans cause lymphedema. VEGFR3 signalling also 
positively regulates angiogenesis [165]. In particular, VEGFR3 is highly expressed in TCs and 
is required for EC sprouting in mice and zebrafish [165, 167]. VEGFR3 forms homodimers as 
well as heterodimers with VEGFR2, which are enriched in TCs and positively influence 
angiogenic sprouting [155, 168]. 
1.2.4.1.2 Fibroblast growth factor (FGF) 
FGF is another pro-angiogenic growth factor, which is stored in the vascular basement 
membrane to serve as a reservoir supply, and is upregulated during active angiogenesis. The two 
most commonly studied forms are FGF-2 or basic FGF (bFGF) and FGF-1 or acidic FGF 
(aFGF), which bind most commonly to the receptor tyrosine kinases FGFR1 or FGFR2. FGF 
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plays important roles in a wide variety of physiological and pathological processes, including 
angiogenesis, vasculogenesis, wound healing, tumorigenesis, and embryonic development [169-
174]. In vitro, FGF increases EC migration, and promotes capillary morphogenesis on collagen 
gels [175, 176]. In addition, bFGF mediates proteolysis of matrix components (via up-
regulation of urokinase receptors), and induces the synthesis of collagen, fibronectin and 
proteoglycans by ECs, and thereby excerts its effects on ECM remodelling during angiogenesis 
[175, 177].  
1.2.4.1.3 Platelet-derived growth factor (PDGF)  
PDGF is a potent mitogen for cells of mesenchymal origin, including smooth muscle cells (SMCs) 
and glial cells. Although -granules of platelets are a major storage site for PDGF, recent studies 
have shown that PDGF can be synthesized by a number of different cell types, such as ECs and 
activated macrophages [178]. PDGF is present in platelets at a concentration of about 23±6 pg/10
6
 
platelets.  In both mouse and human, the PDGF signalling network consists of four ligands, 
PDGFA-D, and two receptors, PDGFRα and PDGFRβ. Most PDGFs function as secreted, 
disulfide-bonded homodimers, but only PDGFA and B can form functional heterodimers [179].  
The PDGFRs are expressed on capillary ECs, and PDGF has been shown to have an angiogenic 
effect [178]. The effect is, however, weaker than that of FGFs or VEGFs, and PDGF does not 
appear to be of importance for the initial formation of blood vessels, since no apparent vascular 
abnormality was observed during early embryogenesis in mice with genes for PDGF or PDGFRs 
inactivated [180]. In contrast, PDGF-BB/PDGFRβ signalling pathway is crucial to recruit mural 
cells (pericytes and SMCs) to blood vessels to maintain structural integrity [180, 181]. Mice 
lacking PDGFB or PDGFRβ display a profound decrease in the number of SMCs and pericytes 
associated with the vessels, leading to unstable, leaky vessels and irregular vascular networks 
[180, 182]. 
1.2.4.1.4 Transforming growth factor-β (TGF- β) 
The TGFβ family encompasses an array of members including the TGFβs (TGFβ1, TGFβ2, and 
TGFβ3), bone morphogenetic proteins (BMPs), growth and differentiation factors, Activins and 
Nodal. TGFβ family members bind to two types of receptors, type I and type II [183]. They are 
secreted in an inactive latent form, which requires cleavage of the latency associated peptide 
domain by proteases, often under acidic conditions.  
TGF-β1 has multiple effects on vascular ECs. In vivo, TGF-β1 induces angiogenesis. Half of 
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mice genetically deficient in TGF-β1 die at E9.5-E10.5 due to defective yolk sac vasculogenesis 
[184]. Ablation of TGFβRII also results in embryonic lethality at E10.5 due to defective 
vasculogenesis in the yolk sac and embryo [185, 186]. In humans, mutations in endoglin, a part 
of the TGFβ receptor complex, and Activin receptor-like kinase-1 (Alk1) result in hereditary 
hemorrhagic telangiectasia, a vascular disorder characterized by arteriovenous malformations, 
severe bleeding [187, 188]. However, in vitro TGF-β1 inhibits EC proliferation [189], migration 
and proteolytic activity [190], downregulates VEGFR2 expression [191], and induces EC 
apoptosis [192-194]. 
1.2.4.1.5 Angiopoietin (Ang) 
Ang is a member of a family of vascular growth factors that play a role in embryonic and 
postnatal angiogenesis. The Ang family of growth factors is comprised of four family members: 
Ang1, Ang2, Ang3 and Ang4. Angs bind the second immunoglubulin motif of Tie2 whereby 
they activate Tie2 and, indirectly, Tie1 in Tie1/Tie2 heterodimers [195]. 
Ang-1-deficient mice die between E11.5 and E12.5 because the embryos are unable to form a 
complex vascular network and exhibit decreased vessel support by mural cells [196]. 
Transgenic Ang1 overexpression or systemic adenoviral delivery resulted in increased vascular 
branching [197-199]. In vitro experiments show the similarly results. Ang1 can induce EC 
proliferation, migration, tube formation and sprouting [200-204], and enhances survival from a 
variety of apoptotic insults [205-208]. 
The role of Ang2 in blood vessel regulation is quite complex. Transgenic overexpression of 
Ang2 leads to a phenotype essentially the same as that seen in the Ang1 knockout, suggesting 
that Ang2 serves as an antagonist for Ang1 [209]. In vitro, Ang2 can prevent Ang1-stimulated 
effects on ECs including migration and Tie2 phosphorylation. Interestingly, it has also been 
shown that Ang2 can activate EC Tie2 at high concentrations [210] or when ECs are plated on 
fibrin or collagen matrix [211, 212]. Indeed, the Ang2 knockout demonstrates that, while Ang2 
is dispensable for embryonic vascular development, Ang2 is required for both the vascular 
regression and sprouting events involved in postnatal ocular angiogenesis [213].  
The less well-studied members of the family, Ang3 and Ang4, are interspecies orthologues 
between mouse and human, respectively. They have different tissue distributions: Ang3 is 
expressed in multiple mouse tissues, whereas Ang4 is specifically present at high levels only in 
human lungs. Ang4 phosphorylates Tie2, whereas Ang3 not only fails to phosphorylate Tie2, but 
 16 
it even inhibits Ang1-induced phosphorylation of Tie2 in human EC [214]. Subsequent studies 
have demonstrated that both Ang3 and 4 are agonists of Tie2 receptor signalling, with Ang3 
being a specific ligand for Tie2 receptors of its own species [215]. Consistent with this notion, 
both Ang3 and Ang4 are able to induce angiogenesis in vivo using the mouse corneal 
micropocket assay [215]. 
1.2.4.1.6 Stromal cell-derived factor-1 (SDF-1) 
SDF-1 (CXCL12) is a constitutively expressed and inducible chemokine that regulates multiple 
physiological processes, including embryonic development and organ homeostasis [216]. SDF-1α, 
which is the predominant isoform found in all organs, is produced by megakaryocytes in the bone 
marrow and contained in α-granules of platelets. It has been shown that platelet-derived SDF-1α 
acts as a chemoattractant and homing signal for CXCR4
+
 EPCs to the sites of neovascularization 
in ischaemic tissues [73, 77]. Other CXCR4
+
 proangiogenic cells are composed of immature and 
mature hematopoietic cells and SMC progenitors, which all have direct or indirect proangiogenic 
properties, are also recruited to the sites of neovascularization in ischaemic tissues. Platelet 
derived SDF-1α has been reported to promote differentiation of cultured CD34+ cells into EPCs 
[76]. Recently, it has been shown that platelet-derived SDF-1α plays a critical role in lung alveoli 
regeneration. After pneumonectomy, platelets-derived SDF-1α stimulates the receptors CXCR4 
and CXCR7 on pulmonary capillary endothelial cells to deploy the angiocrine membrane-type 
metalloproteinase MMP14, stimulating alveolar epithelial cell expansion and neoalveolarization 
[75]. 
1.2.4.2 Anti-angiogenic factors 
Angiogenic inhibitors can be categorized into endogenous and exogenous. Endogenous 
inhibitors include TSP, angiostatin, and endostatin, which exert their effect through inhibition of 
EC survival, proliferation and migration.  
1.2.4.2.1 Thrombospondin (TSP) 
TSP is a family of multifunctional proteins. The family consists of thrombospondins 1-5. TSP-1, 
initially isolated from human platelets [217], became the first endogenous inhibitor of 
angiogenesis to be identified [218]. It is found in concentrations of 31±12 ng/10
6
 platelets. In 
the tumor environment, TSP-1 and TSP-2 serves as potent endogenous inhibitors of 
angiogenesis by activating TGF, thus suppressing tumor angiogenesis. TSP-1 antagonizes 
VEGF in several important ways, via inhibition of VEGF release from the extracellular matrix, 
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direct interaction, and inhibition of VEGF signal transduction [89, 90, 218].  
1.2.4.2.2 Endostatin 
Endostatin is a fragment of collagen XVIII that is present in the vessel walls and basement 
membranes of the vasculature, and plays an important role in EC adhesion and cytoskeletal 
organization. The concentration of endostaton in platelets is 5.6±3.0 pg/10
6
 platelets. Endostatin 
induces EC apoptosis and blocks VEGF-induced migration in ECs, inhibits tumor growth, and 
impairs blood vessel maturation in wound healing. It is thought to interfere with the 
proangiogenic actions of growth factors, such as bFGF and VEGF [97, 98, 219]. However, 
clinical trials showed that endostatin did not result in a significant tumor regression in patients 
with advanced neuroendocrine tumors [220, 221]. 
1.2.4.2.3 Angiostatin 
Angiostatin is a fragment of plasminogen (PLG), which is a cleavage product of several 
enzymes, such as urokinase and tissue-type plasminogen activator. It has both potent 
antiangiogenic activities and anti-proliferative activities toward ECs and cancer cells [222]. 
Recent evidence supports dual antitumor mechanisms for PLG derivatives, one affecting 
angiogenesis and another targeting tumor cells directly [223].  Kringle 5 (K5), like angiostatin, 
is a by-product of the proteolytic cleavage of PLG. A recent study demonstrated that K5 
functions as a competitive antagonist of hepatocyte growth factor [224].  
1.3 THE ROLE OF PLATELET IN ANGIOGENESIS 
The first scientific evidence suggesting that platelets affect vascular endothelium in a way that 
constitutes a basis for new vessel development was reported in the late 1960s [225]. It was 
demonstrated that perfusion of organs with platelet-depleted plasma caused instability of the 
endothelial layer, parenchymal degeneration, and haemorrhages. The addition of platelets 
markedly reduced this injurious effect. In subsequent animal experiments, thrombocytopenia was 
associated with a higher vascular permeability to blood cells and plasma constituents that 
appeared to result from large gaps between ECs. A number of studies suggested that platelets 
promote EC proliferation. As a result of this early research, vascular biologists in the 1960s and 
1970s considered platelet interactions with the vascular wall more trophic or nutritious than 
related to new vessel development. Nevertheless, this research created the foundation for the 
development of the current concepts of platelet involvement in the angiogenic response. Besides 
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the mediators release from α- granules, platelets influence angiogenesis through other two distinct 
mechanisms, the release of microparticles and direct interaction via ligand-receptor interactions. 
1.3.1 Platelet-derived microparticles 
Platelet-derived microparticles (PMPs), the small plasma membrane vesicles (0.1-1 μm) shed 
from platelets upon their activation, constitute approximately 70–90% of microparticles in the 
blood stream [226] and are suggested to be involved in thrombosis, inflammation and 
angiogenesis [227, 228].  Microparticles facilitates communication between neighbouring cells 
via several different mechanisms; by affecting direct cell-cell contacts, by their function as 
transport vesicles carrying and transferring proteins and mRNA between cells, and by direct 
regulation of cell signalling. 
The first suggestion of a PMP-angiogenesis link stemmed from the observation that patients with 
gastric cancer had markedly increased plasma levels of PMPs, which showed a positive 
correlation with levels of proangiogenic factors such as VEGF [229]. Later, it has been shown that 
PMPs could promote EC proliferation, survival, migration and tube formation in vitro [228]. It 
was reported that the active components of PMPs eliciting these responses involved the 
collaborative effect of an unknown lipid component, presumably S1P and the growth factors, 
VEGF and bFGF. Brill et al. [70] extended these findings showing that PMPs, released by 
thrombin-activated platelets induced angiogenesis and improved revascularization following 
myocardial ischemia in vivo. Furthermore, PMPs have been shown to modulate functional 
features of EPCs, which are crucial for their regenerative potential. Treatment of cells with PMPs 
increased expression of mature EC markers on the progenitor cells and promoted both EC 
adhesion and paracrine activity, leading to improved endothelial regeneration. Similar to growth 
factors, PMPs stimulated the growth of EPCs ex vivo, presumably through regulation of 
intracellular signalling pathways involving ERK and phosphoinositide 3-kinase (PI3K)/Akt [228]. 
More recently, Laffont et at. [230] reported that PMPs were internalized by ECs and regulated 
expression of endogenous mRNA levels in ECs via the miRNA in PMPs. Despite PMPs 
representing a relatively new discipline in the field of platelet research, their growing role in a 
range of clinical-based studies highlights their therapeutic relevance, both as a prognostic marker 
for various diseases and new targets for anti-platelet therapies involving thrombotic complications 
and angiogenesis-related disorders. 
1.3.2 Receptors-Ligand interactions 
The first suggestion of platelet regulated angiogenesis through receptor-ligand interactions 
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stemmed from the observation that physical presence of platelets themselves but not the releasate 
from activated platelets is necessary for platelet-promoted EC tube formation in Matrigel [231]. 
Later, it has been shown that platelets promote EC proliferation through P-selectin and CD40L 
[232].  
SDF-1α, which is found in platelet α-granules, expresses on the activated platelets and recruits of 
CD34
+
 progenitor cells to arterial thrombi in vivo [73, 77]. SDF-1α also promotes differentiation 
of cultured CD34+ cells to EPCs [73, 76, 77].  
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2 AIMS OF THE STUDY 
The overall aim of the thesis work is to investigate the role of platelets in angiogenesis and 
improve our understanding of molecular mechanisms underlying platelet angiogenic activities. 
Specifically, we aimed to: 
 Investigate platelet-regulated angiogenic activities of EPCs (Paper I) 
  Study the distinct packaging and release of pro- and anti-angiogenic regulators by platelets 
and their effects on EPC functions (Paper II and Paper III) 
 Elucidate potential impact of platelet activation on de novo protein synthesis of platelet-
derived angiogenic regulators (Paper IV) 
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3 METHODS 
3.1 PLATELETS ISOLATION (PAPER I-IV) 
All blood donors had antecubital veins that allowed a clean venepucture, and denied taking any 
medication during the 2 weeks preceding venepuncture. Blood was drawn without stasis using 
the siliconized vacutainers containing 1:9 (v/v) 3.8% sodium citrate.  
For preparation of platelet-rich plasma (PRP), whole blood was centrifuged at 190 ×g for 20 
min, and upper 2/3 of PRP were collected for further experiments.  
For preparation of washed platelets, the PRP was further centrifuged at 900 ×g for 10 min in the 
presence of 1 µM prostacyclin (PGI2; Sigma-Aldrich; St Louis, MO, USA), and the pellet was 
resuspended in Tyrode’s Hepes buffer containing 1 µM PGI2. Platelets were pelleted again and 
then resuspended in Tyrode’s Hepes buffer. In some cases, PGI2 was replaced by the PGI2 
analogue iloprost (Ciba Geigy), which irreversibly inhibits platelet reactivity. 
For preparation of leukocyte-depleted washed platelets, PRP were isolated from venous blood 
as described above. Contaminating leukocytes in PRP were removed by CD45
+
 bead selection. 
Washed platelets (leukocyte contamination of < 0.001%) were resuspended in serum-free 
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies; Waltham, MA, USA) at a 
concentration of 10
9
 mL
-1
, and treated (37°C, 30 min, or 16 h) with vehicle or thrombin (0.1 U 
mL
-1
; Sigma-Aldrich).  
3.2 PREPARATION OF PLATELET RELEASATES (PAPER I, II & III) 
Washed platelets were stimulated with PAR1-activating peptide (PAR1-AP 10 µM; 
SFLLRNPNDKYEPF-OH from Calbiochem), PAR4-AP (100 µM; AYPGKF-NH2, from 
Sigma-Aldrich), ADP (Sigma-Aldrich), collagen related peptide (CRP; 1 µg/mL, from Dr R. 
Farndale, Cambridge, United Kingdom), or U46619 for 10 min at 37°C. Platelets were 
stimulated for 10 min at 37°C, the samples were centrifuged at 15000 ×g for 10 min at 4°C, and 
the supernatant was collected and stored at -80°C. 
Total platelet releasate was prepared by three freeze/thaw cycles. After centrifugation at 13000 
×g for 10 min at 4°C to deplete debris, the platelet lysate was aliquoted and stored at - 20°C, 
and was used within 4 weeks. 
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3.3 FLOW CYTOMETRIC ANALYSIS (PAPER II-IV) 
3.3.1 Platelet surface marker analyses (PAPER II) 
Aliquots of 5 µl platelets were added to 45 µl of HEPES-buffered saline containing appropriately 
diluted antibodies for the detection of platelet P-selectin (BD; San Diego, CA, USA), PF4 (R&D 
systems; Abingdon, UK), SDF-1 (R&D systems), endostatin (Hycult Biotech; Uden, The 
Netherlands) or VEGF (R&D systems) expression and in the presence of vehicle, PAR1-AP, ADP, 
CRP, U46619, or PAR4-AP. The samples were incubated for 20 min before fixation/dilution with 
0.5% (v/v) formaldehyde saline. Platelet P-selectin, PF4, SDF-1, and VEGF expression was 
reported as the percentages of marker-positive cells in the total platelet population. 
3.3.2 Purity of washed platelets (PAPER IV) 
Purity of the washed platelets was detected by flow cytometry using FITC-GPIX (BD) and PE-
CD45 (Beckman-Coulter; Hialeah, FL, USA). Flow cytometric analysis of the entire cell 
population demonstrated that CD45-depleted platelet preparations contained less than < 0.001% 
CD45 positive cells. 
3.3.3 Characterization of EPCs (PAPER III) 
Early-passage (1-5) EPCs (5×10
4
) were detached by trypsinization (0.01% trypsin/5 mM EDTA; 
Sigma-Aldrich) and incubated at 4°C for 30 to 60 minutes with optimal concentrations of 
fluorescent antibodies or isotype control antibodies in 50 μl PBS with 2% FBS. The samples 
were then washed 2 times, and analyzed using a Beckman-Coulter FC500 flow cytometer.  
3.3.4 EPC apoptosis and cell cycle assay (PAPER III) 
EPCs (2.5×10
4
 in 1000 µL complete medium) were cultured in a 12-well flat-bottom plate. 
After 24 h culture, the medium were replaced by EBM-2 SingleQuot medium without or with 
platelet releasates and cultured for further 18 h. For apoptosis assay, EPCs were harvested, 
washed with PBS, and processed for Annexin V-FITC and propidium iodide (PI) staining with 
an Annexin V-FITC kit (Beckman Coulter). For cell cycle analysis, the cells were harvested and 
resuspended in PBS at the concentration of 10
5
 cells/ml. The cells were fixed with 70% cold 
ethanol and stored at 4°C overnight, and they were then washed with cold PBS and centrifuged. 
The cells were resuspended in 0.25 ml PBS containing RNase (0.2 mg/ml) and incubated at 
37°C for 1 h. Afterwards, the cells were then labelled with PI (1 mg/ml; 1 min). Both samples of 
apoptosis and cell cycle analyses were performed using a FC500 flow cytometer.  
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3.4 IMMUNOFLUORESCENCE MICROSCOPY (PAPER II & III) 
PRP (2×10
8
 cells/mL) was subjected to the treatment with vehicle (resting), PAR1-AP (10 µM), 
PAR4-AP (100 µM), ADP (10 µM), and CRP (1 µg/mL) for 5 minutes at room temperature. 
Thereafter, PRP was fixed for 20 minutes in suspension by the addition of an equal volume of 
4% paraformaldehyde. Fixed platelets in suspension were placed in wells of a 24-well plate, 
each containing a 0.01% poly-L-lysine-coated coverslip, the plate was centrifuged at 250 ×g for 
5 minutes to attach the cells to the coverslip, and then permeabilized with 0.5% Triton X-100 in 
PBS. After blocking with 1% bovine serum albumin-PBS, the samples were incubated 
overnight at 4°C with respective primary antibodies: mouse anti–human SDF-1α (R&D Systems) 
at 1:20; rabbit anti–human PF4 (Santa Cruz Biotechnologies; Santa Cruz, CA, USA) at 1:25; 
rabbit anti–human VEGF (Thermo Fisher Scientific; Waltham, Massachusetts, USA) at 1:500; 
and rabbit anti–human endostatin (abcam; Cambridge, UK) at 1:50. After washing, they were 
incubated with corresponding fluorescent secondary antibodies (DyLight 549 goat anti-mouse 
IgG at 1:50; AlexaFluor-488 goat anti–rabbit IgG at 1:100, AlexaFluor-546 goat anti–rabbit IgG 
at 1:500, and AlexaFluor-488 goat anti–rabbit IgG at 1:100/AlexaFluor-647 donkey anti–mouse 
IgG at 1:100 for double labeling) for 2 hours at room temperature. After thorough washings 
with PBS containing 0.3% Triton X-100 and 0.1% Tween-20, the coverslips were mounted with 
Prolong Gold antifade mounting medium (Life Technologies). Single immunofluorescence and 
SDF-1α/PF4-double immunofluorescence platelet images were acquired using a Leica confocal 
microscope TCS SP2 equipped with a 100× NA1.4 objective. The digital images were assembled 
into composite images using Adobe PhotoShop Version 10.0.1. 
Four-µm-thick cryosections were first blocked with 5% goat serum (ab7481; abcam) for 30 min. 
The sections were then incubated with a rabbit anti-mouse CD31 polyclonal antibody (ab28364; 
abcam) or a nonspecific IgG antibody for 1 h at room temperature, which was followed by 1h 
incubation in the dark with fluorescein isothiocyanate–conjugated goat anti-rabbit secondary 
antibody (ZF-0311; ZSGB-Bio Co., Beijing, China). Fluorescent images were taken with a 
Nikon Eclipse 90i microscope. 
3.5 IMMUNOGOLD-ELECTRON MICROSCOPY (PAPER II) 
For preparation of cryosections, isolated human platelets were fixed with 4% paraformaldehyde in 
0.1 M Na phosphate buffer, pH 7.4. After 2 hours of fixation at room temperature, the cell pellets 
were washed with PBS containing 0.2 M glycine to quench free aldehyde groups from the fixative. 
Before freezing in liquid nitrogen, cell pellets were infiltrated with 2.3 M sucrose in PBS for 15 
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minutes. Frozen samples were sectioned at -120°C, and the sections were transferred to formvar-
carbon coated copper grids and floated on PBS until the immunogold labeling was carried out. An 
aliquot of 4 µl was added to a grid with a formvar supporting film coated with carbon for 5 min. 
The excess solution was soaked off with a filter paper, and the sample was stained with 0.5% 
uranyl acetate in water for 10 sec and air-dried. Grids were floated on drops of 1% BSA for 10 
minutes to block for nonspecific labeling, transferred to 5-µl drops of primary antibody, and 
incubated for 30 minutes. The grids were then washed in 4 drops of PBS for a total of 15 minutes, 
transferred to 5-µl drops of Protein-A gold for 20 minutes, and washed in 4 drops of PBS for 15 
minutes and 6 drops of double distilled water. For double labeling, after the first Protein A gold 
incubation, grids were washed in 4 drops of PBS for a total of 15 minutes and then transferred to a 
drop of 1% glutaraldehyde in PBS for 5 minutes and washed in 4 drops of PBS/0.15 M glycine. 
The second primary antibody was then applied, followed by PBS washing and treatment with 
different size protein A gold as above. In the present thesis work, SDF-1α was probed with 5-nm 
gold protein A, while PF4 was probed by 10-nm gold protein A. Contrasting/embedding of the 
labelled grids was carried out on ice in 0.3% uranyl acetate in 2% methyl cellulose for 10 minutes. 
Grids were picked up with metal loops, leaving a thin coat of methyl cellulose. The grids were 
examined with a Leo 906 transmission electron microscope (Leo GmbH) operating with an 
accelerating voltage of 80 kV and at 60 000x original magnification. Digital images were taken 
with a Morada camera (SiS Münster, Oberkochen, Germany). 
3.6 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) (PAPER II) 
Washed platelets (3×10
8
/mL) were stimulated, and the supernatant was collected and aliquoted 
after centrifugation (14 000 ×g, 5 minutes, 4°C). The levels of VEGF, SDF-1α, PF4, and 
endostatin were determined using corresponding DuoSet ELISA kits (R&D Systems). 
3.7 PROTEIN EXTRACTION AND WESTERN BLOT (PAPER IV) 
Platelet suspensions (10
9
/mL in serum-free DMEM) were incubated in the presence of vehicle 
or thrombin (0.1 U/mL) for 30 min or 16 h at 37
o
C. Platelet pellets were lysed with an NP-40 
lysis buffer (Life Technologies) containing a protease inhibitor cocktail (Sigma-Aldrich) and 1 
mM phenylmethanesulfonyl fluoride (Sigma-Aldrich) after centrifugation at 2000 g for 5 
minutes.  
Platelet lysates were mixed with an equal volume of loading buffer containing 5% β-
mercaptoethanol, and incubated for 5 min at 95
o
C. Proteins were separated on 10% or 16% 
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Novex Tris-Glycine gels (Life Technologies), transferred to a nitrocellulose membrane, and then 
subjected to western blotting. SDF-1α and angiostatin were detected with the 460-SD and 
MAB926 antibodies (both from R&D Systems), respectively, which were subsequently probed 
with the horseradish peroxidase-conjugated goat anti-mouse IgG antibody sc-2031 (Santa Cruz 
Biotechnology). Signal detection was carried out with a Novex ECL chemiluminescence kit 
(Life Technologies). Glyceraldehyde- 3-phosphate dehydrogenase (GAPDH) (Santa Cruz 
Biotechnology) was used as a loading control.  
3.8 RNA EXTRACTION AND QUANTITATIVE REAL-TIME PCR (PAPER IV) 
Platelet suspensions (10
9
/mL in serum-free DMEM) were incubated in the presence of vehicle 
or thrombin (0.1 U/mL) for 30 min or 16 h at 37 °C. Platelet pellets total RNA was extracted 
with a mirVana microRNA isolation kit (Ambion/Applied Biosystems, Austin, TX, USA) after 
centrifugation at 2000 g for 5 minutes.  
mRNA expression levels of SDF-1α and angiostatin were quantified in unstimulated and 
thrombin-activated platelets with quantitative real-time RT-PCR (qRT-PCR) assays. TaqMan 
Gene Expression Assays for SDF-1α/CXCL12 (primer ID: Hs00171022_m1), angiostatin/PLG 
(Hs00264877_m1) and TaqMan Gene Expression Control 18S (ID: Hs99999901_s1) were from 
Applied Biosystems, and qRT-PCR was performed with a StepOnePlusReal-Time PCR system 
(Life Technologies). All real-time experiments were performed in triplicate. Data was 
normalized by the expression of 18S rRNA and expressed either as relative expression (2
-Ct
).  
3.9 EPC CULTURE (PAPER I & III) 
Venous blood was centrifuged at 190 ×g for 20 min to obtain PRP. The remaining blood was 
diluted with same volume PBS, and is overlaid onto Histopaque 1077 (1:1,v/v; Sigma-Aldrich), 
and then centrifuge at 500 ×g for 30 minutes at room temperature to isolate peripheral blood 
mononuclear cells (PBMCs). Collect the PBMCs from the middle layer, and washed twice with 
PBS. At last, isolated PBMCs were resuspended with EGM-2 SingleQuots complete medium, 
which was composed of EBM-2 basal medium, 10% FBS, and the SingleQuots Kit. The PBMCs 
were seeded at 2–4×106 cells per well in a fibronectin-coated 24-well culture plate (Merck 
Millipore; Billerica, MA, USA) and cultured in an incubator at 37 °C with 5% CO2. After 4 days, 
nonadherent cells were discarded, and fresh medium was applied. The adherent cells were 
continually cultured in the complete medium that was changed every 3 days until the first passage. 
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3.10 EPC PROLIFERATION ASSAY (PAPER III) 
EPC proliferation was monitored using a Cell Counting Kit (CCK)-8 (Dojindo; Munich, 
Germany) assay. Briefly, subconfluent cells were detached by trypsinization that was followed 
by neutralization with the complete medium. After a wash, the cells were resuspended in the 
complete medium. EPCs were cultured in triplicates (2.5×10
3
 in 100 µL complete medium per 
well) in a 96-well flat-bottom plate with the complete medium alone or the complete medium 
containing different concentrations of platelet releasates. After 18- and 48-h incubation, the 
CCK-8 colorimetric reagent WST-8 (10 µL per well) was added to each well and further 
incubated for 3 h. Then, the absorbance was measured at 450 nm using a microplate reader. 
3.11 EPC MIGRATION ASSAY (PAPER III) 
EPC migratory function was evaluated using a modified Boyden chamber (BD) with a 
polycarbonate filter with 8-μm pores placed between the upper and lower chambers. 
Subconfluent cells were detached by trypsinization that was followed by neutralization with the 
complete medium. After a wash with PBS, the cells were resuspended in serum-free EBM-2 
medium. In some experiments, EPCs were preincubated with the VGFRE2 inhibitor Ki8751 (10 
µM; Tocris Bioscience; Bristol, UK), the pan-MMP inhibitor GM6001 (20 µM; Tocris 
Bioscience), or the SDF-1α/CXCR4 inhibitor AMD3100 (10 µM; Tocris Bioscience) for 10 min 
at 4°C. Cell suspensions were placed in the upper chamber, and the lower chamber was filled 
with complete medium in the absence or presence of 10% platelet releasates. The EPCs were 
then cultured at 37 °C for 6 or 24 h. Cells remaining on the upper surface of the transwell 
membrane were wiped away gently with a cotton ball, and the cells that had migrated to the 
lower surface were fixed with 4% paraformaldehyde and stained with Giemsa. The magnitude 
of EPC migration was evaluated by counting the migrated cells in 10 random high-power 
microscope fields (HPF). 
3.12 IN VITRO TUBE FORMATION ON MATRIGEL PLATE (PAPER I & III) 
The tube formation assay was performed using the Matrigel (Corning; New York, USA) to 
assess angiogenetic capacity of the EPCs. In brief, EC Matrixgel solution was thawed at 4°C 
overnight, and placed 50 µl/well in a 96-well plate at 37 °C for 1 h to allow the matrix solution 
to solidify. A total of 1×10
4
 cells (100 µl) in EBM-2 SingleQuot medium were added into the 
Matrigel-coated wells and incubated at 37°C. Tubule formation was observed under an inverted 
light microscope (10×), and five representative fields from each well were photographed. The 
branching points of capillary structure were assessed using the Wimasis software (Munich, 
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Germany). 
3.13 IN VIVO VASCULOGENESIS EXPERIMENTS (PAPER III) 
The protocol of in vivo vasculogenesis using a murine model of Matrigel implantation was 
approved by the Institutional Animal Care and Use Committee of the Shandong University. 
Male C57BL/6 mice (8-12 weeks) were obtained from the Animal Experimental Center of the 
Shandong University. 
Matrigel gel (350 µL) containing 10% of supernatant of unstimulated platelets (Rest-PR), 
PAR1-PR, or PAR4-PR was implanted on both flanks of a mouse via subcutaneous injection 
using a 25-gauge needle. Matrigel implants were removed 2 weeks after implantation. After 
Matrigel implants were photographed under a macroscope, one part of the implants was 
cryosectioned for fluorescent immunohistochemical examination. The other part was fixed in 
10% neutralized formalin overnight, embedded in paraffin, and sectioned.  
Hematoxylin and eosin (HE)–stained 4-µm-thick sections were examined for vasculogenesis 
under a Nikon Eclipse 90i microscope (Nikon Corporation, Tokyo, Japan).  
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4 RESULTS 
4.1 PLATELETS PROMOTE ENDOTHELIAL PROGENITOR CELL ANGIOGENESIS 
VIA THEIR MEMBRANE RECEPTORS (PAPER I) 
4.1.1 Development and characterization of human late EPCs  
First we cultured EPC from peripheral blood. PBMCs were harvested and seeded onto 
fibronectin-coated wells. The cells were initially seen as small and round shaped cells. Small 
colonies of EPCs appeared after 2-3 weeks of culture. At confluence, EPCs exhibited a smooth 
cytoplasmic outline and showed a cobblestone appearance similar to cultured HUVECs. Flow 
cytometric phenotyping demonstrated that the EPCs, similar to HUVECs, expressed the 
endothelial markers CD31/platelet endothelial cell adhesion molecule (PECAM-1), 
KDR/VEGFR2, and CD146, but were negative for the leukocyte markers CD45, CD14, or 
CD115. However, some EPCs retained certain levels of CD34 expression, which was not 
detected on HUVECs (Fig. 1). 
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Fig. 1. Endothelial progenitor cell (EPC) development from peripheral blood mononuclear cells 
(PBMCs) and flow cytometric phenotyping. 
4.1.2 Platelets promote EPC tube formation 
The effect of platelets on the angiogenic process was evaluated using the in vitro tube formation 
assay on Matrigel. We found that platelets enhanced EPC tube formation in complete medium 
when the ratio of platelet to EPC was 200:1 (Fig. 2C). 
We also determined the effect of platelets on EPC tube formation in basic medium, which had a 
minimal supplementation of endothelial growth factors. We found that EPCs suspended in the 
medium with only 0.5% FBS had a limited formation of capillary-like structures, and that platelet 
supplementation showed much more rapid and marked enhancement on the capillary-like network 
formation of EPCs (Fig. 2D). For a better elucidation of platelet-promoted tube formation, the 
basic medium and the EPC:platelet ratio of 200:1 were chosen for further experiments. 
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Fig. 2. Platelets promote tube formation of EPCs cultured in complete medium and basic medium. 
4.1.3 Platelets surpass platelet releasate in promoting tube formation of EPCs in 
basal culture medium 
Platelets contain a number of growth factors, which are thought to be the principle force for 
platelet-promoted angiogenesis. We next compared the effects of whole platelets and total platelet 
releasate on EPC tube formation in our system. As seen in Fig. 3A, both platelets and total platelet 
releasate enhanced EPC tube formation. However, platelets promoted angiogenic responses more 
potently than the total platelet releasate (Fig. 3B).  
Since platelets, especially newly released ones, contain abundant mRNAs, platelets can undergo 
de novo synthesis of angiogenic proteins upon activation. To clarify if de novo protein synthesis 
of platelets may account for the more potent enhancements in the presence of platelets, platelets 
   31 
were pre-treated with puromycin (a protein synthesis inhibitor, 100 µM, 30 min), before adding to 
the co-culture system. To prevent platelet activation/secretion during co-culture, PGI2 used during 
platelet isolation was replaced by the PGI2 analogue iloprost. The latter can irreversibly inhibit 
platelet activation. Fig. 3C shows that platelet-enhanced EPC tube formation was minimally 
affected by puromycin or iloprost treatment, seen as unchanged the branching point counts after 
puromycin or iloprost treatment (Fig. 3D). Furthermore, 2% paraformaldehyde fixed platelets 
were also tested for their pro-angiogenic activities. Hence, fixed platelets enhanced tube formation 
from 37.1±7.1/field of EPC alone to 63.9±10.1/field (P<0.05; n=3), which was only slightly 
milder than that by unfixed platelets (Fig. 3E and F). 
 
Fig. 3. Platelets surpass platelet releasate in promoting tube formation of EPCs in basic culture 
medium. 
4.1.4 Surface glycoproteins of platelets promote EPC tube formation 
Glycoproteins are the most abundant proteins on platelet membrane. To assess their possible 
involvements in platelet-promoted tube formation, the iloprost-treated platelets were pre-treated 
with neuraminidase (0.01 i.u./10
7
 platelets), which strips sialic acid residues from glycoproteins. 
Fig. 4 shows that, as expected, supplementation of platelets significantly enhance EPC tube 
formation, and that neuraminidase-treated platelets failed to promote tube formation. 
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Fig. 4. Glycoproteins of the platelet membrane are important for promoting EPC tube formation. 
4.1.5 CD151 in the platelets but not in EPCs is important for platelet-induced tube 
formation of EPCs 
In order to identify platelet membrane proteins responsible for platelet pro-angiogenic effects, we 
employed a panel of blocking agents, including the blocking mAbs against CD151, CD31, P-
selectin, and CD42b, as well as the αIIbβ3 (CD41/CD61) inhibitor SR121566. We found that 
blockade of platelet CD31, CD42b, P-selectin, or αIIbβ3 did not affect platelet-enhanced EPC 
tube formation. In contrast, CD151 blockade markedly reduced platelet-enhanced EPC tube 
formation, while the nonspecific IgG antibody MOPC31 had no effect (Fig. 5A). 
Because both platelets and EPCs express high levels of CD151, we next compared the effects of 
EPC and platelet CD151 blockade on EPC tube formation. It was found that platelet pre-treatment 
by the CD151 blocking MAb PETA3 (clone 50-6) significantly attenuated platelet-enhanced EPC 
tube formation, as compared to untreated platelets. In contrast, pre-incubation of EPCs with the 
CD151 blocking antibody had no effect on platelet-enhanced EPC tube formation (Fig. 5C). 
These results further indicated that platelet-expressed CD151 accounts for platelet enhanced EPC 
tube formation. 
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Fig. 5. CD151 on platelets but not on EPCs is important for platelet-enhanced tube formation of 
EPCs. 
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4.1.6 Integrin α6 is involved in platelet-enhanced EPC tube formation 
Tetraspanins, including CD151, interact with various transmembrane proteins, such as integrins, 
and act as a molecular organizer that regulates the formation of functional clusters of membrane 
proteins. CD151 is known to link to laminin-binding integrins, such as α3β1, α6β1, α6β4, and 
α7β1 [233]. Therefore, the α3 blocking antibody P1B5 (20 µg/ml), the α6 blocking antibody 
GoH3 (20 µg/ml), and the β1 blocking antibody 13 (20 µg/ml) were added in the co-culture 
system. As shown in Fig. 6A, anti-α6 but not anti-α3 MAb decreased platelet-enhanced EPC tube 
formation, while the anti-β1 antibody totally abolished EPC tube formation on matrigel. In 
contrast, RGDS (Arg-Gly-Asp-Ser) peptide, which recognises the RGD motifs in the integrins 
and inhibits integrin receptor function, had no effect on platelet-enhanced EPC tube formation 
(Fig. 6C). 
Platelets express the laminin-binding integrin α6β1 [234, 235], and EPCs express both α6β1 and 
α6β4 [236]. Hence, we next compared the effects of EPC and platelet integrin α6 blockade on 
platelet-enhanced tube formation by pre-incubation of the α6 blocking antibody GoH3. Fig. 6C 
shows that either platelet α6 integrin blockade or EPC α6 integrin blockade similarly reduced tube 
formation. Moreover, simultaneous inhibition of both platelet and EPC α6 integrins showed no 
deference in platelet-enhanced EPC tube formation. These results suggested that integrin α6 was 
important for platelet-promoted EPC tube formation. 
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Fig.6. Integrin α6β1 is involved in CD151-promoted EPC tube formation. 
4.1.7 Platelets increase EPC tube formation through the Src and PI3K pathways 
To further study platelet mediated EPC angiognic responses, the potential involvements of 
different signalling pathways were also investigated. Thus, EPCs were pre-treated with the Src 
kinase inhibitor PP2 (10 µM), the PI3K inhibitor LY294002 (25 µM), or the pan PKC inhibitor 
Ro318220 (10 µM) for 20 min on ice prior to tube formation assays. Fig. 7 shows that PP2 and 
LY294002 effectively inhibited platelet-mediated EPC tube formation, which almost abolished 
the tube formation induced by platelets. Ro318220 mildly attenuated EPC tube formation, which 
produced an approximately 50% inhibition. 
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Fig. 7. Platelets-promoted tube formation involves Src-PI3K signaling of EPCs. 
In summary, platelets can promote angiogenic activities of EPCs independently from platelet-
released mediators. Platelets exert the enhancement via platelet membrane-expressed tetraspanin 
CD151 that promotes EPC tube formation through interaction with α6 integrins and via the Src-
PI3K signalling pathways in EPCs. Together with platelet-released angiogenic regulators, platelet 
membrane components constitute the optimal pro-angiogenic effects of platelets, and may serve 
as a useful target for intervention of platelet angiogenic activities. 
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4.2 DISTINCT PLATELET PACKAGING AND RELEASE OF PROANGIOGENIC 
AND ANTIANGIOGENIC FACTORS ON DIFFERENT PLATELET STIMULI 
(PAPER II) 
Platelets contain both pro- and anti-angiogenic factors. A recent study showed that some pro-
angiogenic and anti-angiogenic factors are stored in separate α-granules, and that thrombin 
receptor PAR1 and PAR4 stimulation induce distinct release of pro- and anti-angiogenic factors 
[63]. Here, we wanted to clarify if distinct packaging of platelet pro- and anti-angiogenic factors 
is a general phenomenon and if and how platelet agonists other than thrombin also induce a 
selective secretion of pro- and anti-angiogenic factors. 
We detected the localization of angiogenic factors within the platelet α-granules by 
immunofluorescent staining. We found that granules were mobilized toward cell periphery, 
often seen in a ring-like staining pattern (arrows) after stimulation (Fig. 8Ai, Bi, Ci, Di). Double 
immunofluorescence labeling demonstrated that most SDF-1α (red) and PF4 staining (green) 
was in separate α-granules, and little colocalization in yellow (arrowheads) was seen in either 
resting (Fig. 8Eiii) or ADP-stimulated platelets (Fig. 8Fiii). We confirmed the presence of 
distinct populations of α-granules in human platelets at the ultra-structural level using immuno-
electron microscopy. As expected, SDF-1α (Fig. 8G) or PF4-probing gold particles (Fig. 8H) 
only present in a subpopulation of α-granules. Double immunogold microscopy confirmed that 
only some α-granules contain both SDF-1α (arrows) and PF4 (arrowheads) gold particles (Fig. 
8I), supporting our findings with confocal microscopy and the notions that the counteracting 
factors are mostly segregated in separate α-granules and that different α-granules are packed 
with different proteins.  
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Fig. 8. Platelets store proangiogenic and antiangiogenic regulators in separate α-granules.  
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4.2.1 Distinct secretion and surface expression of platelet proangiogenic and 
antiangiogenic factors 
We next detected the levels of the angiogenic factors in supernatant by ELISA to determine 
whether platelet activation evokes distinct secretion of angiogenic factors. We found that 
stimulation with PAR1-AP, ADP, and CRP (targeting GPVI) induced massive release of SDF-1α 
and VEGF, as evidenced by significant elevations of SDF-1α (Fig. 9A) and VEGF levels (Fig. 
9B) in the supernatant of washed platelets. These agonists induced, however, much less release 
of the antiangiogenic PF4 (Fig. 9C) or actually no release of endostatin (Fig. 9D). The data 
indicate that PAR1-AP, ADP, and CRP selectively enhance proangiogenic factor release. We all 
know ADP has two receptors on platelets, P2Y1 and P2Y12. To identify which receptor account 
for ADP-induced angiogenic factors release, we activated platelets with ADP in presence of 
vehicle or P2Y12 antagonist. We found the combination of ADP and a P2Y12 antagonist 
showed that ADP-induced VEGF and PF4 release was mainly via P2Y12 activation, whereas 
ADP-induced SDF-1α secretion was primarily via P2Y1 receptor engagement. In contrast, 
PAR4-AP triggered marked release of PF4 (Fig. 9C) and endostatin (Fig. 9D) but limited release 
of SDF-1α (Fig. 9A) and VEGF (Fig. 9B). Thus, PAR4-AP stimulation promotes a selective 
release of platelet antiangiogenic factors. Furthermore, platelet secretion of angiogenic factors 
seems to be a rapid process. The maximal PAR1-stimulated VEGF release was reached in less 
than 5 minutes, with VEGF levels increased from undetectable of resting platelets to 49.8 ± 1.8, 
50.6 ± 0.6, and 49.9 ± 0.6 pg/mL at 5, 15, and 30 minutes of stimulation, respectively. Similarly, 
PAR4-stimulated endostatin release peaked at 5 minutes (89.1 ± 10.6 vs 0.9 ± 0.1 ng/mL of 
resting platelets, and 81.3 ± 11.9 ng/mL after 30 minutes stimulation; n=3). 
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Fig. 9. Distinct secretion of platelet proangiogenic and antiangiogenic factors.  
In summary, proangiogenic factors and antiangiogenic factors are mostly packing in distinct 
populations of α-granules in platelets, and different platelet stimuli evoke distinct secretion of 
proangiogenic and antiangiogenic factors. PAR1, ADP, and GPVI stimulation favors 
proangiogenic, whereas PAR4 promotes antiangiogenic, factor release. 
   41 
4.3 PAR1-STIMULATED PLATELET RELEASATE PROMOTES ANGIOGENIC 
ACTIVITIES OF ENDOTHELIAL PROGENITOR CELLS MORE POTENTLY 
THAN PAR4-STIMULATED PLATELET RELEASATE (PAPER III) 
4.3.1 Neither PAR1-PR nor PAR4-PR has any effect on EPC proliferation, cell 
cycle or apoptosis  
Given that PAR1 and PAR4 stimuli induce selective platelet release of proangiogenic and 
antiangiogenic factors. Our follow-up study was thus to investigate if PAR1-stimulated platelet 
releasate (PAR1-PR) and PAR4-PR regulate angiogenic properties of EPCs in different manners. 
We investigated the influence of platelet releasates on EPC proliferation. We found that 
supplementation of platelet releasates to cultured EPCs did not alter cell proliferation of 
cultured EPCs (Fig. 10A). There was no difference between PAR1-PR and PAR4-PR or among 
the platelet releasate concentrations of 2.5%, 5%, and 10%. To clarify these surprising results, 
EPC culture with platelet releasates was prolonged to 48 h. The releasates were again found to 
have no effect on EPC proliferation (Fig. 10B). To further elucidate the potential influences of 
platelet releasates on EPC proliferation, we monitored cell cycle and apoptosis. Fig. 10C, D 
show that neither 10% PAR1-PR nor 10% PAR4-PR significantly influenced EPC cell cycle 
distribution in the G0/ G1, S, or G2/M phase. Fig. 10E, F show that addition of either PAR1-PR 
or PAR4-PR to cultured EPCs did not alter the percentages of the total Annexin V
+
 EPCs, which 
included early and late apoptotic cells, as well as necrotic cells. 
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Fig. 10. Influences of platelet releasates on EPC proliferation, cell cycle, and apoptosis. 
4.3.2 Both PAR1-PR and PAR4-PR enhance EPC migration and tube formation 
We next investigated the effect of platelet releasates on EPC migration by using a Boyden 
chamber chemotactic migration assay. After a 6-h culture, we found that the numbers of 
migrated EPCs were increased in the wells containing PAR1-PR (relative increase by 25%, 
compared with complete medium alone) and PAR4-PR (29%; P < 0.05 for both; n = 4) but not 
PAR1-AP or PAR4-AP (Fig. 11A). As the incubation time increased to 24 h, the numbers of the 
migrated cells were further increased, with a relative enhancement by 44% in PAR1-PR–
containing wells and by 40% in PAR4-PR–containing wells (P < 0.05 for both; n = 6) (Fig. 11B). 
Moreover, there was no difference between the treatments with PAR1-PR and PAR4-PR on 
either observation time points. 
We also examined the effects of platelet releasates on EPC tube formation with an in vitro 
Matrigel assay. We found both PAR1-PR and PAR4-PR markedly enhanced tube formation of 
the EPCs, seen as increased densities of the capillary network in the complete medium (Fig. 
11E). When capillary network branch points were counted, PAR1-PR and PAR4-PR both 
increased the branch numbers of capillary networks, compared with those without platelet 
releasates (Fig. 11F).  
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Fig. 11. Platelet releasates enhance EPC migration and tube formation. 
4.3.3 Impact of platelet-released VEGF, MMP, and SDF-1α on EPC migration and 
tube formation 
Activated platelets release a number of angiogenic regulators, such as VEGF, MMP, and SDF-1α, 
which can enhance EC migration and/or tube formation. We therefore investigated whether these 
factors were involved in the enhancements of platelet releasates on EPC angiogenic responses by 
using corresponding inhibitors. To more clearly elucidate the effects of platelet releasates on EPC 
migration, we chose to use the EBM-2 medium containing 10% FBS but not the growth factor 
cocktail of SingleQuots Kit as the chemotactic source in the migration experiments. Fig. 12 shows 
that, in the absence of platelet releasates (open bars), VEGF receptor blockade by Ki8751 (10 µM) 
did not reduce EPC migration toward FBS-containing medium in the lower chamber. MMP 
inhibition by GM 6001 (20 µM) and SDF-1α/CXCR4 inhibition by AMD3100 (10 µM) were 
associated with lower numbers of migrated EPCs but without a statistical significance. The 
migration of EPCs was significantly increased in the presence of 10% PAR1-PR and 10% PAR4-
PR (P < 0.05 for both; n = 4) in a similar manner. The enhancements were reduced by MMP 
inhibition and SDF-1α/CXCR4 inhibition (P < 0.05 for all). 
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Thus, we next chose to use EPCs suspended in the medium containing only 0.5% FBS in the tube 
formation experiments to clearly demonstrate the effects of platelet-released angiogenic regulators 
on EPC tube formation. In this system, EPCs suspended in the basal medium had a limited 
formation of capillary-like structures after 6-h culture (Fig. 12C; with branch numbers at 33.5± 
5.4 per field). Supplementation of 1 µM PAR1-AP (31.2 ± 9.0 per field) or 10 µM PAR4-AP 
(34.0± 7.5 per field), which corresponded to their levels in 10% platelet releasates, had no effects 
on EPC capillary network formation. However, both PAR1-PR and PAR4-PR significantly 
enhanced the capillary-like network formation of EPCs (Fig. 12C, D). More profound 
enhancement was seen with PAR1-PR that increased the branch number to 60.7 ± 9.3 per field 
(representing the relative increase of 80.3%; P < 0.05). Fig. 12D also shows that PAR1-PR– and 
PAR4-AP– enhanced EPC tube formations were markedly inhibited in the presence of an 
inhibitor of either VEGFR2, MMP, or SDF-1α. Interestingly, each of those inhibitory agents 
virtually abolished the enhancing effects of PAR1-PR or PAR4-PR (Fig. 12). These data may 
suggest that platelet releasate–enhanced EPC tube formation is exerted as a cooperation of 
multiple platelet-derived angiogenic regulators. 
 
Fig. 12. Effects of VEGF, MMP, or SDF-1α inhibition on platelet releasate–enhanced EPC 
migration and tube formation. 
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4.3.4 PAR1-PR promotes stronger vasculogenesis in vivo than PAR4-PR 
Using a murine model of vasculogenesis in vivo with the implantations of Matrigel containing 
10% platelet releasates, Fig. 13A shows that 2-week implantation of Matrigel plugs containing 
supernatant of unstimulated platelets did not induce marked new vessel formation. However, 
Matrigel plugs containing PAR1-PR induced significant vasculogenesis, and the new vessels were 
much better developed, as evidenced by a more intense branching of the new vessels (Fig. 13B). 
In contrast, Matrigel plugs containing PAR4-PR induced considerably less vasculogenesis, and 
the new vessels were less well developed and with limited branches (Fig. 13C), compared with 
these in PAR1-PR plugs. When branch numbers of newly formed vessels were counted, both 
PAR1-PR and PAR4-PR induced significantly more vasculogenesis than did Rest-PR, while 
PAR1-PR–induced new vessel formation was much more marked than those by PAR4-PR (Fig. 
13D). Immunofluorescent staining of the endothelium-specific marker CD31 confirmed that there 
was more intense vasculogenesis in PAR1-PR Matrigel plugs (Fig. 13F) than in PAR4-PR (Fig. 
13G) or Rest-PR Matrigel plugs (Fig. 13E). The H&E staining of paraffin-embedded Matrigel 
plug sections also revealed that new vessel formation was rare in Rest-PR plugs (Fig. 13I), most 
intense and well developed in PAR1-PR plugs (Fig. 13J), and thinly scattered in PAR4-PR plugs 
(Fig. 13K). Moreover, PAR1-PR and PAR4-PR induced a more intense cell infiltration, likely 
blood-borne inflammatory cells, into the plugs. 
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Fig. 13. PAR1-PR promotes stronger vasculogenesis in vivo than PAR4-PR. 
In summary, the platelet releasates from both PAR1- and PAR4-stimulated platelets enhanced 
EPC migration and tube formation, but had no influence on EPC proliferation. However, PAR1-
PR–enhanced capillary network formation of EPCs was more profound, and the enhancement was 
even more evident in the mouse model of Matrigel implantation. The enhancements involve 
multiple factors, as intervention of either VEGF, SDF-1α, or MMP abolished platelet releasate–
enhanced tube formation of EPCs. 
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4.4 THROMBIN INDUCES DE NOVO PROTEIN SYNTHESIS OF ANGIOGENIC 
FACTOR IN HUMAN PLATELETS (PAPER IV) 
4.4.1 Thrombin stimulation induces de novo protein synthesis of SDF-1α in 
human platelets 
Albeit an anuclear cell, platelets can actively synthesize proteins closely related to their 
functions, which is a newly recognized but yet important feature of “late” platelet activation 
events [104]. Hence, it is interesting to reveal if platelet activation initiates protein synthesis of 
angiogenic regulators. 
We isolated leukocyte-depleted washed platelet, and activated with thrombin. We found that the 
intensity of SDF-1α-immunoreactive bands were decreased after thrombin stimulation for 30 
min, indicating reduced levels of SDF-1α in platelets, i.e. SDF-1α release upon stimulation. 
However the SDF-1a immunoblotting intensity was partially restored after 16 h of culture, 
suggesting de novo protein synthesis of SDF-1α. As expected, the immunoblotting intensity of 
the loading control glyceraldehyde-3-phosphate dehydrogenase remained largely unchanged 
throughout the experiments. When SDF-1α immunoblotting intensity was quantified, SDF-1α 
levels were significantly decreased by 30 min of thrombin stimulation, and showed a rebound 
after 16 h, albeit to a level lower than that before stimulation (Fig. 14C). Similar to that of SDF-
1α, thrombin stimulation markedly reduced the intensity of angiostatin-immunoreactive bands 
(Fig. 14B,D), indicating that thrombin also induced platelet secretion of angiostatin. In contrast 
to the rebound seen with SDF-1α, the reduction in platelet angiostatin content remained after 16 
h of cell culture. 
 
Fig. 14.Thrombin stimulation induces de novo protein synthesis of SDF-1α in human platelets. 
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4.4.2 Thrombin stimulation induces SDF-1α mRNA maturation in human 
platelets 
Next we investigated whether changes in platelet protein content were related to mRNA 
maturation. To demonstrate the expression of functional SDF-1α mRNA, we chose a 
quantitative real-time RT-PCR (qRTPCR) with primers spanning an exon–exon junction of 
SDF-1a/CXCL12, which allowed measurement of mature mRNA of SDF-1α but not of pre-
mRNA; 18S rRNA was used as an endogenous control. The cDNA synthesis was performed 
with 200 ng of total RNA and a High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). Fig. 15A shows that qRT-PCR readily detected 18S rRNA in both unstimulated 
and thrombin-activated platelets. For SDF-1α, however, no mature mRNA was detected in 
unstimulated platelets, whereas significant amplification of mature SDF-1α mRNA was found in 
thrombin-activated platelets after approximately 30 PCR cycles. These results suggest that 
thrombin stimulation induced maturation of SDF-1α mRNA, and that the mRNA was expressed 
at a relatively low level as compared with 18S rRNA. When the angiostatin/plasminogen (PLG) 
qRT-PCR assay was used, no significant angiostatin/PLG mRNA was detected in either 
unstimulated or thrombin-stimulated platelets (Fig. 15B).   
 
Fig. 15.Thrombin stimulation induces mRNA maturation of SDF-1α in human platelets. 
In conclusion, platelets contain SDF-1α mRNA transcripts. Thrombin stimulation induces SDF-
1α mRNA maturation, which leads to de novo synthesis of SDF-1α after activation. The newly 
synthesized SDF-1a may reinforce platelet angiogenic activities in remodelling and repair of the 
injured vessels. 
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5 GENERAL DISCUSSION 
The present thesis work provides new evidence supporting that platelets are an important player 
in angiogenesis. We have shown that platelets store pro-angiogenic and anti-angiogenic 
regulators in separate α–granules, and may release them distinctly upon different platelet stimuli. 
Distinct releases of platelet angiogenic regulators display distinct impacts on angiogenesis. 
PAR1-PR, which is rich in pro-angiogenic regulators, promotes angiogenesis more profoundly 
both in vitro and in vivo as compared to PAR1-PR, which is prone anti-angiogenic regulator 
release. Apart from platelet-released mediators, we have also identified that platelet membrane 
components tetraspanin CD151 and α6β1 integrin, as well as EPC α6β1 integrin are important 
for platelet-enhanced EPC tube formation. Furthermore, our results indicate that platelets 
undergo de novo protein synthesis of SDF-1α upon activation. 
During the last decades, accumulating evidence indicates that platelets are closely involved in 
angiogenesis [13, 17]. Investigators have identified numerous pro- and anti-angiogenic factors 
that are stored in platelets and released after platelet activation. The pro-angiogenic factors 
found in platelets include VEGF, PDGF, bFGF, IGF-1, S1P, and MMPs. The anti-angiogenic 
factors found in platelets include TSP-1, PF4, PAI-1, and angiostatin [13, 17]. In most of the 
experiments, platelets play a proangiogenic effect. However, to what extent that pro-angiogenic 
properties of platelets are attributed to platelet-release angiogenic factors is an issue to be 
clarified. Some papers suggest that the growth factors released from platelets are not enough for 
the effect.  For instance, Pipili-Synetos et al. [231] found that platelets, but not supernatant of 
matrigel-activated platelets or thrombin-activated platelets, promoted EC tube formation. Kent 
et al. [237] also showed that attachment of fresh platelets, but not addition of platelet releasate, 
stimulated EC proliferation in an organ culture model of arterial injury. In contrast, there are 
also papers showing that ADP-induced platelet releasate and thrombin-induced platelet releasate 
increase EC tube formation and angiogenesis in vivo [66, 69, 238]. The major difference among 
these contradicting papers is that the concentration of platelets used. The studies with negative 
results used the releasates from 1-2×10
7
/ml platelets [69, 231], whilst the reports with positive 
results were using platelet releasates from at least 10 times higher concentrations of platelets (2-
4×10
8
/ml) [69, 238] The present thesis work showed that 10% platelet releasates from 2×10
9
/ml 
increased EPC migration, tube formation, and vasculogenesis in vivo. Thus, platelet releasates 
from physiological concentrations of platelets are able to modulate EC and EPC angiogenesis. 
We also found that platelets had a higher enhancement for angiogenesis than the total platelet 
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releasate, which was consistent with previous paper that the angiogenic responses to platelets 
were more pronounced than that of the platelet releasate [69]. Glycoproteins are the most 
abundant proteins on platelets, and have been suggested to be involved in platelet-mediated 
angiogenesis [231]. Hence, we have demonstrated that platelet membrane glycoproteins 
contribute importantly to platelet-enhanced angiogenic activities of EPCs, because 
neuraminidase treatment abolished platelet-enhanced angiogenesis. We have further identified 
that platelet membrane-expressed tetraspanin CD151 is responsible for the enhancement, and 
demonstrated that CD151 promotes EPC tube formation through interaction with α6 integrins 
and via the Src-PI3K signalling pathways of EPCs. Interestingly, it seems that integrin α6 on 
both EPC and platelet membranes are engaged in the action, because either EPC or platelet 
integrin α6 blockade showed an identical effect in attenuating platelet-enhanced EPC tube 
formation. EPC α6 integrin may interact with laminin-111 present in Matrigel and thereby 
mediate the angiogenesis, as recently demonstrated by Bouvard et al. [239]. Platelet α6β1 
integrin may also interact with the Matrigel laminin-111 or, alternatively, with cell-associated 
laminins produced by EPCs. 
Platelets contain both pro- and anti-angiogenic factors and release them after activation. Recent 
studies indicate that platelets may store pro- and anti-angiogenic regulators in separate α-
granules, and release differentially upon different stimuli. Ma et al. [62] first demonstrated that 
the thrombin receptor PAR1 and PAR4 stimulation induce differential releases of pro- and anti-
angiogenic regulators. PAR1-specific stimulation induces VEGF release, whereas PAR4 
activation resultes in endostatin release. Subsequently, Italiano et al. [63] further revealed that 
VEGF and endostatin are stored into separate α-granules in both platelets and megakaryocytes. 
In line with these findings, paper II of the present thesis showed that platelets mostly store 
proangiogenic and antiangiogenic regulators in separate α-granules, and that platelets 
selectively release proangiogenic or antiangiogenic regulators upon different stimuli [66].  
However, there is also evidence showing that platelet angiogenic regulators may be randomly 
packed into platelet α-granules but released with a distinct protein cluster, and that the distinct 
release may depend on activation intensity and secretion kinetics of platelets. Van Nispen tot 
Pannerden et al. [240] identified two different types of α-granules, spherical and tubular α-
granules. They also noted that those tubular granules contain fibrinogen but not VWF, and those 
spherical α-granules, on the other hand, contain both fibrinogen and vWF. However, tubular 
granules were identified in only proximately 16% of the platelets. Kamykowski et al. [64] failed 
to show evidence for coclustering of angiogenic regulators into functionally distinct α-granule 
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populations using a super-resolution analysis of 15 different human α-granule proteins and 
quantified 28 different pair-wise comparisons. Jonnalagadda et al. [65] further performed a 
systematic quantification of granule secretion using microenzyme-linked immunosorbent assay 
arrays for 28 distinct α-granule cargo molecules in response to four different agonists, and 
showed that there were no obvious functional patterns to PAR1- or PAR4-stimulation. They 
found that PAR4-AP did not induce release of as many different molecules as did thrombin, 
convulxin, or PAR1-AP. More recently, van Holten et al. [241] showed that the most abundant 
α-granule proteins were released in similar quantities from platelets after maximum stimulation 
with either PAR-1 or PAR-4 using the mass spectrometry based quantitative proteomics.  
Although distinct releases of platelet angiogenic regulators upon different stimuli are still under 
a debate, it has been reported that different platelet releasates may exert counteracting effects on 
angiogenesis [66]. Thus, ADP-induced platelet releasate promoted EC tube formation, whereas 
TXA2-induced platelet releasate inhibited EC tube formation [66]. However, recently, Etulain et 
al. [242] showed that both PAR1-PR and PAR4-PR promoted angiogenesis in a similar pattern. 
In paper III, we found that platelet releasates by the thrombin receptor PAR1 and PAR4 
stimulation only result in different degrees of enhancements on angiogenesis. Our results 
demonstrated that intervention of VEGF, SDF-1α, or MMP each abolished the enhancements of 
EPC tube formation by platelet releasates. Our findings suggest that pro-angiogenic effects of 
platelet releasates require a cooperation of multiple angiogenic regulators. Moreover, our data 
indicated that the selective release of platelet angiogenic regulators mainly concerns the 
different release levels of platelet angiogenic regulators, and that the absolutely selective release 
is seen only with endostatin secretion triggered by PAR4 stimulation. Platelets release numerous 
angiogenic regulators after stimulation via PAR1 or PAR4, and the overall outcome of 
proangiogenic effects seem depend on the negotiation of all factors in the platelet releasates. 
The presence of mRNA in platelets was detected more than two decades ago. However, we are 
only beginning to understand the roles of mRNA in platelet biology and human diseases, 
because platelet mRNA levels are low and the principal functions of platelets in haemostasis 
and thrombosis mainly concern rapid processes of platelet activation. It is now recognized that 
platelets are also closely involved in nonhaemostatic processes, such as inflammation and 
angiogenesis, which are chronic processes. There is also growing evidence that platelet mRNA 
expression patterns are altered in human disease [243].  
Since the discovery of synthesis of Bcl-3 by activated platelets [244], platelets are found to 
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synthesize more and more proteins, such as TSP-1, IL-1β, PAI-1, and TF [104]. These findings 
also reveal that, similar to other cells, protein syntheses of platelets are preceded by signal-
dependent pre-mRNA splicing. This process yields mature transcripts that are translated into 
precursor (IL-1β) and active (TF) proteins [105-108]. However, if platelet activation initiates 
protein synthesis of angiogenic regulators has not been thoroughly investigated. In paper IV, we 
found that thrombin stimulation induced de novo protein synthesis of pro-angiogenic SDF-1α, 
but not anti-angiogenic angiostatin [245]. However, the impact of the do novo synthesized 
protein on angiogenesis and/or vessel remodelling still needs further investigations. 
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6 CONCLUSIONS AND SUMMARY 
Platelets can promote angiogenic activities of EPCs through membrane components. Platelets 
exert the enhancement via platelet membrane-expressed tetraspanin CD151 that promotes EPC 
tube formation through interaction with α6 integrins and via the Src-PI3K signalling pathways in 
EPCs. Together with platelet-released angiogenic regulators, platelet membrane components 
constitute the optimal pro-angiogenic effects of platelets, and may serve as a useful target for 
intervention of platelet angiogenic activities. 
Platelets contain both pro- and anti-angiogenic factors. The proangiogenic factors and 
antiangiogenic factors are mostly packing in distinct populations of α-granules in platelets, and 
different platelet stimuli evoke distinct secretion of proangiogenic and antiangiogenic factors. 
PAR1, ADP, and GPVI stimulation favors proangiogenic, whereas PAR4 promotes 
antiangiogenic, factor release. 
The platelet releasates from both PAR1- and PAR4-stimulated platelets enhanced EPC migration 
and tube formation, but had no influence on EPC proliferation. However, PAR1-PR–enhanced 
capillary network formation of EPCs was more profound, and the enhancement was even more 
evident in the mouse model of Matrigel implantation. The enhancements involve multiple factors, 
as intervention of either VEGF, SDF-1α, or MMP abolished platelet releasate–enhanced tube 
formation of EPCs. 
Thrombin stimulation induces SDF-1a mRNA maturation, which leads to de novo synthesis of 
SDF-1α after activation. The newly synthesized SDF-1a may reinforce platelet angiogenic 
activities in remodelling and repair of the injured vessels. 
Our findings support the notion that platelets are a versatile coordinator of angiogenesis. 
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7 FUTURE PERSPECTIVES 
During the past decade, numerous data have advanced our knowledge and understanding of the 
role of EPCs in vascular regeneration and endothelial reparation. Still, many questions remain to 
be addressed. 
EPCs have become a potential therapy in the treatment of cardiovascular diseases. However, it is 
still limited by several factors for clinical applications, such as cell senescence and differentiation 
during long time culture and functional impairment from patients with cardiovascular diseases. It 
should be of great interest to develop a new culture method to rescue EPCs from cellular 
senescence. Moreover, there is a need to improve EPC functions from the cardiovascular diseases 
patients for the further autologous transplantation. 
Besides that, EPCs have some properties that are different from mature ECs, such as EPCs have 
higher proliferative capacity and more resistant against apoptosis under serum deprivation than 
mature ECs. Moreover, infusion of EPC, but not of mature ECs, promotes neovascularization 
after ischemia. So it could be a potent target to improve endothelia function if we can identify the 
major molecular by comparison the difference between EPC and EC. 
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